2-Ethyl-2-azabicyclo<2.2.2>octan, N-Ethyl-isochinuclidin | 92145-51-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-Ethyl-2-azabicyclo<2.2.2>octan, N-Ethyl-isochinuclidin
• 英文别名: N-Ethyl-isochinuclidin；2-ethyl-2-aza-bicyclo[2.2.2]octane；2-Ethyl-2-azabicyclo[2.2.2]octane
• CAS: 92145-51-2
• 化学式: C₉H₁₇N
• 分子量: 139.241
• InChiKey: VBHLXDYKLVBDSY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF
  申请人：Tang Peng Cho

  公开号：US20120184543A1

  公开（公告）日：2012-07-19

  Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed.

  二氢吡啶酮衍生物、其制备方法及药用途被揭示。特别是，根据通用式(I)表示的新二氢吡啶酮衍生物，其中通用式(I)的每个取代基如描述中所定义，它们的制备过程，包含所述衍生物的药物组合物以及它们作为治疗剂的用途，特别是作为Plk激酶抑制剂的用途被揭示。
• [EN] CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS<br/>[FR] COMPOSÉS DE 2,4-DIOXOPYRIMIDINE INHIBANT CD73
  申请人：GILEAD SCIENCES INC

  公开号：WO2021222522A1

  公开（公告）日：2021-11-04

  The present disclosure provides pyrimidine dione compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors. The compounds can be used alone or in combination with other anti-cancer agents.

  本公开提供了嘧啶二酮类化合物及其药物组合物，用于治疗癌症，包括实体肿瘤。这些化合物可以单独使用或与其他抗癌药物联合使用。
• OXAZOLIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1
  申请人：Itai Akiko

  公开号：US20100113448A1

  公开（公告）日：2010-05-06

  Disclosed is a compound which is useful as an 11β-hydroxysteroid dehydrogenase type 1 inhibitor. A compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein R 1 is optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycle or optionally substituted heterocyclealkyl, X is —O—, —NR 3 —, —NR 3 C(═O)— or —NR 3 S(═O) 2 —, R 2 is optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl, R 3 is hydrogen or optionally substituted alkyl.
• AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND MEDICINAL APPLICATION THEREOF
  申请人：Shanghai Hengrui Pharmaceutical Co., Ltd.

  公开号：US20170037044A1

  公开（公告）日：2017-02-09

  Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof are provided. Specifically, amide derivatives represented by general formula (I) are provided. The amide derivatives represented by general formula (I) can be used as a therapeutic agent, particularly as an inhibitor for microsomal prostaglandin E synthase-1 (mPGES-1), and also to treat and/or prevent diseases or illnesses such as inflammation and/or pain etc. The definition of each substituent group in general formula (I) is the same as the definition in the description.
• MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
  申请人：Miller Mark Thomas

  公开号：US20170196862A2

  公开（公告）日：2017-07-13

  The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.